Roche wins US clearance for Wilserdly, tied to ESR1 testing in breast cancer
The US regulator has approved giredestrant plus everolimus for biomarker-selected advanced breast cancer, giving Roche a marketed product in the endocrine-resistant setting.
Roche said on 16 November 2026 that the US Food and Drug Administration has approved Wilserdly (giredestrant), an oral drug that degrades the oestrogen receptor, to be taken together with everolimus. The decision gives the Swiss group a US-marketed product in advanced breast cancer, where it competes in a segment defined by tumour genetics.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.